A look at earnings from the view of macro-economists and market technicians
A bottom-up view of earnings from professional equity analysts
Documentation, research, and support for the information provided
Sign in using:
Don't have an account?
Earnings Whisper ®
2nd Quarter June 2021
Revenue: $21.95 Mil
4:00 PM ET
Monday, May 10, 2021
Adamas Reports First Quarter 2021 Financial Results
What do you expect when ADMS reports earnings?
Where is ADMS's stock price going from here?
Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company's portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas.
Merck & Co.